Anebulo Pharmaceuticals (ANEB) Liabilities and Shareholders Equity (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $9.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 40.52% year-over-year to $9.4 million; the TTM figure through Dec 2025 stood at $46.3 million (up 63.07% YoY), while the FY2025 annual figure was $12.1 million, up 198.19% from the prior year.
• Liabilities and Shareholders Equity retreated to $9.4 million in Q4 2025 per ANEB's latest filing, from $10.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $21.7 million in Q2 2021 and bottomed at $2.5 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $12.6 million across 5 years, with a median of $13.1 million in 2025.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 615.0% — and 2024, when it slumped 72.72%.
• Anebulo Pharmaceuticals' Liabilities and Shareholders Equity stood at $19.0 million in 2021, then retreated by 10.95% to $16.9 million in 2022, then plunged by 55.59% to $7.5 million in 2023, then surged by 111.19% to $15.8 million in 2024, then tumbled by 40.52% to $9.4 million in 2025.
• Business Quant data shows ANEB's Liabilities and Shareholders Equity at $9.4 million in Q4 2025, $10.7 million in Q3 2025, and $12.1 million in Q2 2025.